Introduction: The gold standard for the determination of the erythrocyte sedimenta-
disorders or therapeutic responses. ESR remains one of the essential prognostic criteria in giant cell arteritis (GCA) and polymyalgia rheumatica. 
| Overview of the previously published guidelines for performance of the ESR and of the "gold standard" method
From the very beginning, there were significant variations in the methodology used to perform ESR testing. [3] [4] [5] [6] The National Committee for Clinical Laboratory Standards (NCCLS; now called Clinical Laboratory Standards
Institute [CLSI]) and the International Council for Standardization in
Haematology (ICSH) responded by publishing methods for standardizing performance of the ESR. 3, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The Westergren method was selected as the reference method as it was reliable, reproducible, and sensitive. 5, 6 The defined standardized method recommended the use of blood diluted with trisodium citrate dihydrate and specified the technique, including dimensions and characteristics of the pipettes and how to report the results, namely as millimeter sedimentation after 60 minutes.
In 1977, new documents were published by the ICSH and the NCCLS. 3, 7 Acceptable modifications to the routine method were stated, such as pipettes made of plastic rather than glass, as well as the use of EDTA-anticoagulated blood.
In 1988, both NCCLS and ICSH published new guidelines for quality assurance. 16 In 1993, an ICSH group published new recommendations, stressing the importance of ensuring that measurements obtained in different laboratories were comparable. 12, 14 Several new methods, some of them automated or semiautomated, became available in 2001. The technical innovations incorporated in these new instruments significantly improved on the existing procedures. Some of the new methods had shorter testing times, others had reduced the biohazards of ESR testing as the samples were aspirated from closed tubes, avoiding exposure of personnel to blood. The CLSI H02-A4 standard covered the new instruments that were available at the time.
14 Despite these efforts, the international standardization and comparability of ESR methods remained unsatisfactory. ICSH and CLSI therefore made new recommendations in 2010 and 2011. 11, 17 The ICSH document recognized that automated methods were routinely used in many laboratories, using diluted or undiluted samples. The reference procedure remained based on the Westergren method. The document stated that all new technologies, instruments, or methodologies had to be evaluated against the Westergren reference method before being introduced into clinical use and that "systems that give the results as the Westergren method with diluted blood at 60 minutes or normalized to 60 minutes are the only ones of clinical value." It was recommended that manufacturers provide data on the reliability and trueness of any method and instrument, as well as calibration and control procedures.
A protocol for evaluation of the routine/working method against the standardized method was also described, clearly indicating the statistical methods that should be used for the comparative evaluation.
This brief summary shows how the procedures published by the ICSH and NCCLS/CLSI, despite some limitations, have for over 40 years provided the guidance needed to ensure comparability of data obtained in different laboratories throughout the world and improved the precision and accuracy of the test.
At present, standardization in this field is facing automation and novel methods to measure the ESR. These pressures are inevitable because of increased workloads, cuts in laboratory personnel and budgets, and the need for closed blood collection tubes to ensure employee safety. The new technologies and instruments address many of these concerns and are therefore attractive to many laboratories.
Because of these changes, there is a need for a continuing improvement in the harmonization of the ESR. 
| Aim of this paper

| MATERIALS AND METHODS
A Working Group consisting of the six authors of this study was convened by the ICSH. The members of the Working Group were chosen by the Chair of the ICSH in collaboration with the Chair of the Working Group. Experts had to meet at least one and preferably several of the following five criteria:
• Being responsible for the standardization and quality improvement of laboratory hematology in national or local settings (eg, being responsible for organizing EQA schemes, developing recommendations in their country/local area).
• Having participated in ICSH and/or CLSI standardization projects.
• Published original peer-reviewed articles and/or edited books on laboratory hematology.
• Were familiar with ISO Standards as well as technical requirements in their own country.
• Geographic diversity; an attempt was made to have as many different areas represented as possible. To complete our survey of changes in ESR testing, we also reviewed trends toward integrating ESR instruments into laboratory automation systems. This was carried out by talking to experienced colleagues and instrument manufacturers and reviewing information about laboratory automation on the Internet.
| RESULTS
| Findings of the literature review
Review of the peer-reviewed literature yielded over 20 original papers on novel ESR instrumentation. Most publications compared the new instruments to the Westergren method. Some of these papers
were not fully conclusive, stressing the importance of careful study
designs. Other investigators compared new instruments to modified
Westergren methods, to each other, or to C-reactive protein (CRP).
Interestingly, different authors sometimes arrived at very different conclusions about the clinical usefulness, or lack thereof, of the same methodology. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] At least two groups, using different technologies, modified reference ranges to compensate for systemic biases of the instruments they used. 23, 28 In addition, one of these publications also adjusted their ESR reference ranges for the patients' hematocrit.
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One publication presented data that paraproteins had different effects on ESR results depending on the methodology used. 29 Van der
Maas and co-workers reported that when ESR results obtained with the Westergren method were replaced by an alternate method, the Disease Activity Score 28 (DAS 28), a validated tool to monitor patients with rheumatoid arthritis, misclassified patients. 22 All these observations point toward consequences of the inherent differences between the Westergren method and the modified and alternate methods and the need for standardization and harmonization.
Comparisons of the ESR with CRP were reported by several groups. [30] [31] [32] [33] [34] Kermani and colleagues reported that the CRP was slightly more sensitive for a positive temporal artery biopsy than the ESR; however, the difference was minimal. 32 A group from Texas found that one in eight patients will have discordant ESR and CRP results. 
| Findings of the review of EQA and other data
We collected EQA and other data from Australia, China, Europe (with separate data sets from Ireland, Italy, and the United Kingdom, as well as from a pan-European survey), Korea, the USA, and Canada ( 
| Role of ESR instruments in automated laboratories
Most ESR instruments are stand-alone instruments. However, many • A similar approach is to transport samples via an automation track to an ESR instrument. A robotic arm, which is part of the ESR instrument, then takes the tube from the track and moves it into the instrument. After aspiration of an aliquot of the sample, it is returned to the track by the robotic arm. This approach is in use in the Starrsed TL (RR Mechatronics, Zwaag, the Netherlands).
• It is possible that manufacturers will integrate rapid ESR methods as part of future CBC testing platforms.
Advantages of integration of ESR technology into automated systems include savings on labor, no need for aliquots and therefore more efficient use of sample volumes, shorter turnaround times, and minimal exposure of laboratory staff to biohazards. Disadvantages include possible higher costs of instrumentation.
| DISCUSSION/RECOMMENDATIONS
| Modified and alternate methods to measure the ESR
As outlined, the traditional Westergren method has been replaced in most laboratories with novel instrumentation. Our surveys indicate that worldwide two-thirds of all laboratories now use modified or alternate ESR test methods for the measurement of the ESR ( 36, 37 It is unclear whether the novel methods will similarly reflect low fibrinogen levels.
Reasons for the rapid, worldwide adaptation of these methods in- with maintenance of optimal blood stability. 38 The increased automation reduces the probability of human error and increases economic efficiency. Direct interfacing of the instruments with the electronic medical record (EMR) allows error-free, instantaneous data transmission (Table 4 ). This long list of advantages portends a future with even wider use of the modified and alternate technologies, indicating the urgent need for clear labeling and standardization of the new instruments.
| RECOMMENDATIONS
The following recommendations were established based on the expert opinions of the six members of the Working Group. Each member had a primary responsibility in terms of collection and/or analysis of data. After all the data were collected, the Chair combined the contributions into a first draft, which then was circulated repeatedly to the members of the Working Group. 
| CLASSIFICATION OF ESR METHODS
The Working Group classifies ESR methods into three categories:
• The Westergren method: This is the gold standard method described in the 2011 ICSH review, without modifications.
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• Modified Westergren methods: These are methods based on the Westergren methodology with some modifications, for example, a shorter assay time and use of no diluent or different diluents than recommended by ICSH.
• Alternate ESR Methods: These are instruments that are not based on the Westergren method. Instead, these devices use novel approaches such as centrifugation or photometric rheology.
| NEW ICSH RECOMMENDATIONS FOR MODIFIED AND ALTERNATE ESR METHODS
| Manufacturers' Obligations
Standardization (or better harmonization) can be obtained when new technologies are carefully validated against the gold standard method (Westergren). As the modified and alternate methods do not necessarily measure the same pathophysiological processes as the Westergrenbased method, the Working Group recommends that these methods be clearly marked by the manufacturers as modified or alternate ESR methods in all promotional materials, package inserts, and user manuals.
In contrast to most other laboratory assays, the ESR does not measure a well-defined analyte with a specific molecular structure, but rather a physicochemical phenomenon, perhaps best described as a "measurand." This means that a true standardization of ESR assays is by definition impossible. A more appropriate term is "gold standard," as represented by the Westergren method.
The following are the Minimal Validation Procedures and Performance
Criteria for manufacturers of new modified and alternate ESR methods (Table 5 ). These criteria are based on previous ICSH documents.
• Accuracy: At least 60 samples, spanning the entire analytical range • Precision:
a. Intrarun precision should be determined with at least three patient samples (one each in the low, middle, and high thirds of the analytical range), each analyzed ten times during the same 8-hour period.
b. Inter-run precision should be determined with QC material in the normal and abnormal range, analyzed three times a day on five consecutive days.
• Interference studies should be performed for anemia, hemolysis, and lipemia, as well as any other potential interference. Presence or absence of interferences should be noted in the instrument specifications and the standard operating procedures, and if interference is present, the level where interference begins to affect ESR results should be indicated. If appropriate samples from patients with anemia, hemolysis, and lipemia cannot be obtained, spiking of samples or adjustments in hematocrit can be performed.
• The analytical measurement range should be determined by establishing the highest and lowest measurements that correlate with the predicate method.
• Carryover: Potential carryover should be assessed by running patient samples with high and low protein levels and viscosity, in accordance with CLSI document EP10-A3-AMD.
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• Reference Range Studies: Age-and gender-dependent differences in ESR reference ranges have been well documented in the literature. 40 Age-and gender-specific reference ranges should therefore be determined in accordance with CLSI document EP28-A3c. 41 It is understood that some alternate methods will have reference ranges that may significantly differ from the Westergren method. These values can be mathematically transformed into Westergren units. 
| User Obligations for modified and alternate ESR methods
• Laboratories that want to introduce modified and alternate ESR methods are obligated to follow all applicable regulatory and institutional requirements. This includes making certain that where and analysis with the predicate method and the new system can be performed.
• The analytical measurement range should be confirmed by determining the highest and lowest measurements that the laboratory was able to confirm with the predicate method. This can be performed with the samples used for the accuracy study.
• Carryover: Potential carryover should be assessed for each instrument by the laboratory, to avoid spuriously elevated or low results.
This can be performed by analyzing patient samples with high and low protein levels and viscosity, in accordance with CLSI document EP10-A3-AMD.
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• Precision studies should be performed for intrarun and inter-run precision.
a. Intrarun precisions should be determined with three patient samples of whole blood (one each in the low, middle, and high thirds of the analytical range), each analyzed ten times during an 8-hour period.
b. Inter-run precision should be determined with a normal and an abnormal (elevated) level of QC material, analyzed three times a day for five consecutive days.
• Interferences reported by the manufacturer should be listed in the laboratory's standard operating procedure and shared with customers, as applicable.
• If possible, the laboratory should establish its own reference ranges for the population served by enlisting healthy donors of all age groups. If this is not feasible, the laboratory can verify the reference ranges recommended by the manufacturer, as described in CLSI Guideline EP28-A3c. 41 If necessary, the laboratory may have to adjust for altitude. 42, 43 • In addition to routine verification studies performed for any new samples from the patient population in whom the method will be used.
• In addition, the laboratory should issue a change of method notice and should consider initially adding an interpretative comment to every result that summarizes the sensitivity and specificity of the method for various disease states.
• Purchase and use commercial QC material spanning the analytical range of their instruments. If commercial QC material is not available, the procedure described by Plebani and Piva for the use of fresh human whole blood for the daily QC of the ESR can be used.
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QC should be run at least once every day that that the instrument is in use.
• The laboratory should subscribe to an EQA program specific for its method. If an EQA program suitable for the laboratory's method is not available, regular (two to three times a year) comparison studies with other laboratories should be performed.
| CONCLUSIONS
Over 120 years after the first description of the ESR, the clinical relevance of this "imperfect test" has been questioned. 45 However, the test remains one of the most frequently performed procedures in many hematology laboratories, and novel ways to obtain ESR results safer, faster, cheaper, and with higher accuracy and precision continue to become available. It will be up to the manufacturers, users, and regulators to make sure that the new technologies are chosen, validated and verified, and employed appropriately, for the ultimate benefit of patients, their families, and care providers.
